Combining anti-CD70 mAb blockade with imatinib therapy effectively promoted cell death of human CD34+ CML stem/progenitor cells in vitro, as well as in a patient-derived xenograft model [94]. This evidence concerns the gene CD70 and chronic myelogenous leukemia, BCR-ABL1 positive.